JOURNAL OF PEDIATRIC INFECTION, cilt.9, sa.1, ss.25-33, 2015 (ESCI)
Objective: Incidence of Acinetobacter infections is increasing both in Turkey and worldwide. Based on their ability to develop resistance, Acinetobacter species can cause morbidity and mortality, particularly in newborns, children, immunocompromised patients, and critically ill intensive care patients. There are limited treatment options, particularly in carbapenem resistant Acinetobacter strains. In this study, we aimed to compare in vivo activities of colistin sulphate, tigecycline, and cefoperazone-sulbactam in an experimental mouse sepsis model.